Radiogardase

Prussian Blue, Insoluble (Radiogardase®)



Indications and Usage


  • This oral ion-exchange drug is indicated for decorporation of cesium and thallium and has been shown to be highly effective for Cs-137 contamination.
  • Prussian blue is not FDA approved for rubidium.
  • It is benign, with the exception of occasional constipation.
  • Prussian blue turns the stool color blue.
  • Marketed as 0.5 gram (500 mg) insoluble Prussian blue in gelatin capsules for oral administration.
  • Prussian blue is available only by prescription.
  • PO Dosing
    • Adults (Two adult recommended dosing regimens exist.)
      • From Goiânia accident data (PDF - 6.4 MB):
        • 1-3 grams (2-6 capsules) PO tid
        • Usual dose starts at 1 g (2 capsules) PO tid for up to 3 weeks (or longer, as required).
        • Doses up to 10-12 g/day for more significantly contaminated adults may be used
      • FDA drug label (PDF - 208 KB): 3 g (6 capsules) PO tid
    • Children 2-12 years old
      • FDA drug label (PDF - 208 KB): 1 g (2 capsules) PO tid. Capsules may be opened and mixed with food.
    • Children <2 years old
      • CAUTION: Use has not been approved by the FDA. (IND or EUA may be required)
  • Duration of treatment
    • Typically, a minimum of a 30 day course has been recommended, but clinical and availability conditions may alter this recommendation.
    • It is useful to obtain bioassay and whole body counting to assess treatment efficacy.
    • Duration of therapy depends on total body burden and response to treatment.
  • The CDC has included Prussian blue in the Strategic National Stockpile (SNS), a special collection of drugs and medical supplies that CDC keeps to treat people in an emergency.
  • Other names for Prussian blue:
    • Berlin blue
    • Ferric ferrocyanide
    • Ferric(III) hexacyanoferrate
    • Ferric hexacyanoferrate (II)
    • Iron blue
    • Radiogardase-Cs
    • Fe4[Fe(Cn6)]3

top of page



Reference Links


CDC resources

FDA resources

Other

top of page



How to Get?


top of page



References

  1. Dose assessment of inhaled radionuclides in emergency situations (Public Health England [PHE], formerly Health Protection Agency [HPA]/United Kingdom and Treatment Initiatives After Radiological Accidents (TIARA) Project/European Commission, August 2007)
  2. Management of Persons Contaminated With Radionuclides: Handbook (NCRP Report No. 161, Vol. I), National Council on Radiation Protection and Measurements, Bethesda, MD, 2008, Decorporation Therapy by Drug (pp. 201-209). [Note: NCRP 161 supersedes NCRP 65.]
  3. Management of Persons Contaminated with Radionuclides: Scientific and Technical Bases (NCRP Report No. 161, Vol. II), National Council on Radiation Protection and Measurements, Bethesda, MD, 2010, Appendix H.3 Goiânia Incident (pp. 908-915).
  4. Cesium-137 in the Environment: Radioecology and Approaches to Assessment and Management, (NCRP Report No. 154), National Council on Radiation Protection and Measurements, Bethesda, MD, 2006